Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-07-18
1997-04-29
Shaver, Paul F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 2, 514789, 514825, 514885, 514886, 514889, 514903, A01N 4342, A61K 3147
Patent
active
056249381
ABSTRACT:
This invention provides a pharmaceutical composition which comprises an amount of chloroquine effective to block MHC Class I recycling and an amount of a CD8+ T cell stimulatory agent effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, and a pharmaceutically acceptable carrier.
This invention provides a method for treating an autoimmune disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the autoimmune disease.
This invention provides a method for treating cutaneous lymphoma disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the cutaneous lymphoma disease.
This invention provides a method for treating rheumatoid arthritis in a subject which comprises administering to the subject an amount of the pharmaceutical composition of chloroquine and a CD8+ T cell stimulatory agent effective to treat rheumatoid arthritis.
Finally, this invention provides a method of depleting CD4+ T cells which comprises contacting to the cells an amount of chloroquine effective to block MHC Class I recycling and a CD8+ T cell stimulatory agent in an amount effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, so as to thereby deplete CD4+ T cells.
REFERENCES:
patent: 2233970 (1941-03-01), Andersag et al.
patent: 4806537 (1989-02-01), Roberts
patent: 4831033 (1989-05-01), Roberts
patent: 5149688 (1992-09-01), Ando et al.
patent: 5183687 (1993-02-01), Hunter
patent: 5234683 (1993-08-01), Hunter et al.
Arnason, B.G.W. (1993) Interferon Beta in Multiple Sclerosis, Neurology 43:641-643 (Exhibit 3).
Augustijns, P., et al. (1992) Chloroquine Levels in Blood During Chronic Treatment Of Patients with Rheumatoid Arthritis, Eur. J. Clin, Pharmacol 42:429-433 (Exhibit 4).
Brooks, P.M. et al. (1986) Slow-acting Anti-Rheumatic Drugs, The Clinical Pharmacology of Anti-Inflammatory Agents eds. Taylor and Franers, London, pp. 86-91 (Exhibit 5).
Clark, P., et al. (1993) Hydroxychlorquine Compared with Placebo in Rheumatoid Arthrisis, Ann. Intern. Med. 119:1067-1071 (Exhibit 6).
Connolly, K.M., et al. (1988) alteration of Interleukin Activity and the Acute Phase Response in Adjuvant Arthritis Rats Treated with Disease Modifying Antirheumatic Drugs, Agents and Actions 25:94-105 (Exhibit 7).
Edelson, R.L. (1991) Photopheresis: A Clinically relevant Immunobiologic Response Modifier, Ann. N.Y. Acad. Sci 636:154-164 (Exhibit 8).
Fowler, P.D. et al. (1984) Report on Chloroquine and Dapsone in the Treatme Of Rheumatoid Arthritis: A 6-Month Comparative Study, Ann. Rheum. Dis. 43:200-204 (Exhibit 9).
Fox, R.I. (1993) Mechanism of Action Of Hydroxychloroquine as an Artirheumat Drug, Sem Arthr. Rheum. 23:82-91 (Exhibit 10).
Gaur, A., et al. (1993) Requirement for CD8+ Cells in T Cell Receptor Peptide-Induced Clonal Unresponsiveness, Science 259:91-94 (Exhibit 11).
Gautum, A.M. and Glynn, P. (1989) Lewis Rat Lymphoid Dendritic cells Can Efficiently Present Homologous Myelin Basic Protein to Encephalitogenic Lymphocytes, J. Neuroimmun 22:113-121 (Exhibit 12).
Gilman, A.G., et al. (1990) Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th ed., New York, pp. 981-983 (Exhibit 13).
Howell, M.D., et al. (1989) Vaccination Against Experimental Allergic Encephalomyelitis with T Cell Receptor Peptides, Science 246:668-670 (Exhibit 14).
Hurvitz, D. and Hirschhorn, K. (1965) Suppression of In vitro Lymphocyte responses by Chloroquine, New engl. J. Med. 273:23-26 (Exhibit 15).
IFNB Multiple Sclerosis Study Group (1993) Interferon Beta 1-b is Effective in Relapsing-Remitting Multiple Sclerosis. I., Neurology 43:655-661 (Exhibit 16).
Jack, A.S., et al. (1990) Cutaneous T-Cell Lymphoma Cells Employ a Restricted Range of T-Cell Antigen Receptor Variable Region Genes, Am. J. Pathol. 136:17-21 (Exhibit 17).
Jacobs, L., et al., (1987) Intrathecally Administered natural Human Fibroblas Interferon Reduces Exacerbations on Multiple Sclerosis, Arch. Neurol. 44:589-595 (Exhibit 18).
Jaing, H., et al. (1992) Role of CD8+ t Cells in Murine Experimental Allergi Encephalomyelitis, Science 256:1213-1215 (Exhibit 19).
Kawabe, Y. and Ochi, A. (1991) Programmed Cell Death and Extrathymic Reducti Of V Beta 8+ CD4+ T Cells in Mice tolerant to Staphylococcus aureus Enterotoxin B, Nature 349:245-249 (Exhibit 20).
Kawabe, Y. and Ochi, A. (1990) Selective Anergy of V Beta+, CD+4 T Cells in Staphyloccoccus Enterotozin B-Primed Mice, J. Exp. Med. 172:1065-1070 (Exhibit 21).
Koh, d. et al. (1992) Less Mortality But More Relapses in Experimental Allergic Encephalomyelitis in Cd8+-/-Mice, Science 256:1210-1213 (Exhibit 22).
Lipsky, P.E. (1983) Remission-Inducing Therapy in Rheumatoid Arthritis Am. J. Med. Oct. 31, 1983:40-49 (Exhibit 23).
Mackenzie, A.H. (1983) Dose Refinements in Long-Term Therapy of Rheumatoid Arthritis with Antimalarials, Am. J. Med. Jul. 18, 1983:40-45 (Exhibit 24).
Maksymowych, W. and Russell, A.S. (1987) Antimalarials in Rheumatology: Efficacy and Safety, Sem. Arthr. Rheum. 16:206-221 (Exhibit 25).
Noronha, A., et al. (1990) Interferon Beta Augments Suppressor Cell Funtio in Multiple Sclerosis, Ann. Neurol. 27:207-210 (Exhibit 26).
Paty, D.W. et al. (1993) Interferon beta-1b is Effective in Relapsing-Remitting Multiple Sclerosis, Neurology 43:662-667 (Exhibit 27).
Physicians' Desk Reference (1992) 46th ed. New Jersey, pp. 2067-2069 (Exhibit 28).
Reid, P.A. and Watts C. (1990) Cycling of Cell-Surface MHC Glycoproteins Through Primaquine-Sensitive Intracellular Compartments, Nature 346:655-657 (Exhibit 29).
Rekant, S.I. and Becker, L.E. (1973) Auto-Immune Annular Erythema, Arch. Dermatol. 107:424-426 (Exhibit 30).
Rellahan, B.L., et al. (1990) In Vivo Induction of Anergy in Peripheral V Beta 8+T Cells by Staphylococcal Enterotoxin B, J. Exp. Med. 172:1091-1100 (Exhibit 31).
Salmeron, G. and Lipsky, P.E. (1983) Immunosuppressive Potential of Antimalarials, Am. J. Med. 75:19-24 (Exhibit 32).
Sperber, K., et al. (1993) Selective Regulations of Cytokine Secretion by Hydroxychloroquine: Inhibition of Interleukin 1 Alpha (IL-1-alpha) and IL-6 in Human Monocytes and T Cells, J. Rheum. 20:803-808 (Exhibit 33).
Sun, D., et al. (1988) Suppression of Experimentally Induced Autoimmune Encephalomyelitis by cytolytic T--T Cell Interactions, Nature 332:843-845 (Exhibit 34).
Titus, E.O. (1989) Recent Developments in the Understanding of the Pharmacokinetics and Mechanism of Action of Chloroquine, Ther. Drug. Monit. 11:369-379 (Exhibit 35).
Tse, D.B., et al. (1986) Recycling Class I MHC Antigens: Dynamics of Internalization, Acidification, and Ligand-Degradation in Murine T Lymphoblasts, J. Mol. Cell Immunol. 2:315-329 (Exhibit 36).
Vandenbark, A.A. et al. (1989) Immunization with a Synthetic T-Cell Receptor V-Region Peptide Protects Against Experimental Autoimmune Encephalomyelitis, Nature, 341:541-544 (Exhibit 37).
Shaver Paul F.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Use of chloroquine to treat multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of chloroquine to treat multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of chloroquine to treat multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-705992